Personalized ANtibodies for GastroEsophageal Adenocarcinoma (PANGEA): Primary efficacy analysis of the phase II platform trial (NCT02213289).

Daniel V.T. Catenacci,Samantha Lomnicki,Leah Chase,Bryan Peterson,Kelly Moore,Ugne Markevicius,Lindsay Alpert,Namrata Setia,John Hart,Chih-Yi Liao,Uzma D. Siddiqui,Kiran K. Turaga,Mitchell C. Posner,Kristen Kipping-Johnson,Sunil Narula,Murtuza M. Rampurwala,Yuan Ji,Theodore Karrison,Blase N. Polite,Hedy L. Kindler

Personalized ANtibodies for GastroEsophageal Adenocarcinoma (PANGEA): Primary efficacy analysis of the phase II platform trial (NCT02213289).

2020

356Background: 1-yr OS is ~40% for HER2- & ~55% for HER2+ advanced (aGEA). Targeted therapies (tx) have had limited benefit due to molecular heterogeneity. Methods: This phase 2a study of a persona...

Keywords:

Adenocarcinoma
Antibody
Internal medicine
Medicine
Oncology
Pathology
gastroesophageal adenocarcinoma
molecular heterogeneity

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations